Sign in
Active, not recruitingPhase 2

APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer

Key facts

Who runs it
Azienda Ospedaliero-Universitaria Careggi
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
180 people, planned
Started
11 Mar 2023
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • SBRT on all sites of metastatic disease+Apalutamide
Record updated
17 November 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients who have signed written informed consent
  • Adult patients ≥ 18 years
  • Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions *, **
  • All lesions must be amenable to SBRT in judgment of treating radiation oncologist ***
  • Patients with metastatic recurrence after previous radical prostatectomy or definitive radiotherapy will be included in the trial, provided that radical approach on prostate is administered
  • Androgen deprivation therapy (ADT) started ≤ 6 months before enrollment
  • Patients should be eligible to Apalutamide treatment

Who cannot take part

  • Presence of visceral disease
  • De novo metastatic disease
  • Any condition for which, in the opinion of the treating physician, SBRT should not be proposed or could be contraindicated
  • Any contraindication to the use of Apalutamide

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone. However, stereotactic body radiotherapy (SBRT) showed to improve outcomes of oligometastatic patients if compared to systemic therapy alone within modern randomized trial, including a mixed cohort of different pathologies. However, there are no trials specifically exploring the benefit offered by SBRT in oligometastatic mHSPC treated with Apalutamide if compared to Apalutamide alone associated to Androgen deprivation therapy. Thus, a randomized trial was designed to test specifically the hypotesis that SBRT will improve outcome in a selected population of oligometastatic mHSPC treated with Apalutamide and ADT, undergoing baseline staging according to local reimbursability.

The 2 groups in the trial

  • ControlExisting treatment, for comparison

    Androgen Deprivation therapy and Apalutamide

    Treatment: SBRT on all sites of metastatic disease+Apalutamide

  • TreatmentTreatment being tested

    Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease

    Treatment: SBRT on all sites of metastatic disease+Apalutamide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
APalutamide and stEReotactic Body Radiation Therapy for Low Burden Metastatic Hormone senSItive Prostate Cancer, a rANdomized Trial - PERSIAN
Record updated
17 November 2026